May 13, 2004 — About one third of sildenafil nonresponders respond to intraurethral alprostadil treatment for erectile dysfunction (ED), according to the results of a small study published in the May ...
A 63-y-old man attended the erectile dysfunction clinic. He was initially treated with intracavernosal injection of 20 μg alprostadil (Viridal®). Due to the poor response he used intraurethral ...
Men with stable CAD who are being treated for erectile dysfunction (ED) have a lower risk of dying if their medication is a phosphodiesterase 5 (PDE5) inhibitor rather than alprostadil, observational ...
Men with coronary artery disease who used phosphodiesterase-5 (PDE-5) inhibitors for erectile dysfunction had fewer adverse cardiovascular events than those taking the prostaglandin drug alprostadil ...
Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...
The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago. A study from ...
Erectile dysfunction (ED), the inability to achieve and/or maintain an erection sufficient for satisfactory sexual intercourse is traditionally considered an age dependent male dysfunctional disorder, ...
SAN DIEGO, March 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI), announced today that the Mexican Patent Office ("MPO") will grant an additional patent for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results